The European Commission Has Approved Marinus Pharmaceuticals' Ztalmy (Ganaxolone) Oral Suspension For The Adjunctive Treatment Of Epileptic Seizures Associated With Cyclin-dependent Kinase-like 5 Deficiency Disorder In Patients Two To 17 Years
Portfolio Pulse from Benzinga Newsdesk
The European Commission has approved Marinus Pharmaceuticals' Ztalmy (Ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with Cyclin-dependent kinase-like 5 deficiency disorder in patients aged two to 17 years.
July 31, 2023 | 11:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marinus Pharmaceuticals' Ztalmy has been approved by the European Commission for the treatment of epileptic seizures in patients aged two to 17. This could potentially increase the company's market share and revenues.
The approval of Ztalmy by the European Commission opens up a new market for Marinus Pharmaceuticals. This could lead to an increase in the company's market share and revenues, which could potentially have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100